Automate Your Wheel Strategy on EXEL
With Tiblio's Option Bot, you can configure your own wheel strategy including EXEL - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol EXEL
- Rev/Share 8.181
- Book/Share 7.4602
- PB 5.1888
- Debt/Equity 0.0884
- CurrentRatio 3.513
- ROIC 0.232
- MktCap 10420848130.0
- FreeCF/Share 2.7473
- PFCF 13.9157
- PE 17.519
- Debt/Assets 0.0672
- DivYield 0
- ROE 0.2774
- Rating A-
- Score 4
- Recommendation Buy
- P/E Score 2
- DCF Score 5
- P/B Score 1
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | EXEL | RBC Capital Mkts | Outperform | Sector Perform | $45 | $50 | July 8, 2025 |
| Upgrade | EXEL | Stephens | Equal Weight | Overweight | -- | $60 | June 24, 2025 |
| Downgrade | EXEL | Wells Fargo | Overweight | Equal Weight | -- | $36 | Feb. 24, 2025 |
| Upgrade | EXEL | Morgan Stanley | Equal Weight | Overweight | $30 | $40 | Jan. 27, 2025 |
| Downgrade | EXEL | Oppenheimer | Outperform | Perform | -- | -- | Jan. 24, 2025 |
| Downgrade | EXEL | BMO Capital Markets | Outperform | Market Perform | $36 | $40 | Dec. 20, 2024 |
| Downgrade | EXEL | BofA Securities | Buy | Neutral | $35 | $39 | Dec. 17, 2024 |
| Reiterated | EXEL | RBC Capital Mkts | -- | Outperform | $30 | $34 | Oct. 16, 2024 |
| Initiation | EXEL | UBS | -- | Neutral | -- | $30 | Sept. 19, 2024 |
News
3 Reasons Growth Investors Will Love Exelixis (EXEL)
Published: June 25, 2025 by: Zacks Investment Research
Sentiment: Positive
Exelixis (EXEL) could produce exceptional returns because of its solid growth attributes.
Read More
Exelixis (EXEL) Surges 7.4%: Is This an Indication of Further Gains?
Published: June 24, 2025 by: Zacks Investment Research
Sentiment: Positive
Exelixis (EXEL) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Read More
Here's Why Exelixis (EXEL) is a Strong Momentum Stock
Published: June 24, 2025 by: Zacks Investment Research
Sentiment: Positive
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Read More
EXEL Stock Rises on Positive Data From Colorectal Cancer Study
Published: June 24, 2025 by: Zacks Investment Research
Sentiment: Positive
EXEL jumps 7.4% as STELLAR-303 trial hits key survival goal in colorectal cancer, boosting hopes for an approval of zanzalintinib.
Read More
Exelixis, Inc. (EXEL) Soars to 52-Week High, Time to Cash Out?
Published: June 24, 2025 by: Zacks Investment Research
Sentiment: Positive
Exelixis (EXEL) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Read More
Exelixis: Zanzalintinib MOA Overcomes Competing CRC Regorafenib Treatment
Published: June 23, 2025 by: Seeking Alpha
Sentiment: Positive
Exelixis is a strong buy due to robust CABOMETYX sales growth, with Q1 2025 revenues up 36% year-over-year and raised full-year 2025 guidance. Positive phase 3 STELLAR-303 results for zanzalintinib plus TECENTRIQ in non-MSI-high metastatic colorectal cancer opens significant new market opportunities. Expansion of the zanzalintinib pipeline into additional indications (nccRCC, HNSCC) and ongoing regulatory milestones could further drive shareholder value.
Read More
Exelixis Announces Zanzalintinib in Combination with an Immune Checkpoint Inhibitor Improved Overall Survival in STELLAR-303 Phase 3 Pivotal Trial in Patients with Metastatic Colorectal Cancer
Published: June 22, 2025 by: Business Wire
Sentiment: Neutral
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced positive topline results from the STELLAR-303 phase 3 pivotal trial in which zanzalintinib in combination with atezolizumab (Tecentriq®) demonstrated a statistically significant improvement in overall survival (OS) versus regorafenib in the intent-to-treat (ITT) population of patients with previously treated non-microsatellite instability (MSI)-high metastatic colorectal cancer (CRC). These topline findings are from.
Read More
Here's Why Exelixis (EXEL) is a Strong Value Stock
Published: June 18, 2025 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
EXEL or ARGX: Which Is the Better Value Stock Right Now?
Published: June 17, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Exelixis (EXEL) and argenex SE (ARGX). But which of these two companies is the best option for those looking for undervalued stocks?
Read More
Why Is Exelixis (EXEL) Down 7.2% Since Last Earnings Report?
Published: June 12, 2025 by: Zacks Investment Research
Sentiment: Negative
Exelixis (EXEL) reported earnings 30 days ago. What's next for the stock?
Read More
3 Underfollowed Stocks on the Move Now (OLO, PLMR, EXEL)
Published: June 11, 2025 by: Zacks Investment Research
Sentiment: Positive
I like to keep things simple—I look for stocks that have strong price momentum, top Zacks Ranks, reasonable valuations and high growth forecasts. Momentum indicates that the market recognizes a winner, the Zacks rank reflects improving analyst expectations, a reasonable valuation limits downside risk and growth is what ultimately drives stock returns.
Read More
3 Reasons Why Growth Investors Shouldn't Overlook Exelixis (EXEL)
Published: June 09, 2025 by: Zacks Investment Research
Sentiment: Positive
Exelixis (EXEL) possesses solid growth attributes, which could help it handily outperform the market.
Read More
Are You Looking for a Top Momentum Pick? Why Exelixis (EXEL) is a Great Choice
Published: June 06, 2025 by: Zacks Investment Research
Sentiment: Positive
Does Exelixis (EXEL) have what it takes to be a top stock pick for momentum investors? Let's find out.
Read More
Exelixis Stock Surges 28% YTD: Should You Buy Now or Sell?
Published: June 04, 2025 by: Zacks Investment Research
Sentiment: Positive
EXEL gains 28.2% YTD, driven by Cabometyx growth, pipeline progress and an increase in stock buyback authorizations.
Read More
Why Exelixis (EXEL) is a Top Momentum Stock for the Long-Term
Published: June 04, 2025 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
Here's Why Exelixis (EXEL) is a Strong Growth Stock
Published: June 02, 2025 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
Top 4 Value Stocks With Impressive PEG Ratios to Buy Now
Published: May 30, 2025 by: Zacks Investment Research
Sentiment: Positive
Here are the four discounted PEG-based value stocks that qualify our screening criteria- URBN, XRAY, LTM and EXEL.
Read More
Why Exelixis (EXEL) is a Top Value Stock for the Long-Term
Published: May 28, 2025 by: Zacks Investment Research
Sentiment: Positive
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Read More
Exelixis (EXEL) Upgraded to Buy: What Does It Mean for the Stock?
Published: May 23, 2025 by: Zacks Investment Research
Sentiment: Positive
Exelixis (EXEL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Read More
Earnings Estimates Moving Higher for Exelixis (EXEL): Time to Buy?
Published: May 23, 2025 by: Zacks Investment Research
Sentiment: Positive
Exelixis (EXEL) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Read More
3 Reasons Why Growth Investors Shouldn't Overlook Exelixis (EXEL)
Published: May 23, 2025 by: Zacks Investment Research
Sentiment: Positive
Exelixis (EXEL) possesses solid growth attributes, which could help it handily outperform the market.
Read More
EXEL vs. ARGX: Which Stock Is the Better Value Option?
Published: May 23, 2025 by: Zacks Investment Research
Sentiment: Neutral
Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Exelixis (EXEL) and argenex SE (ARGX). But which of these two stocks offers value investors a better bang for their buck right now?
Read More
EXEL Reports Superior Efficacy Data From Kidney Cancer Study Cohort
Published: May 23, 2025 by: Zacks Investment Research
Sentiment: Positive
Exelixis' zanzalintinib/Opdivo combo shows superior efficacy for treating kidney cancer in an expansion cohort of the phase Ib/II STELLAR-002 study.
Read More
Product Performance, Big Money Lift Exelixis
Published: May 23, 2025 by: FXEmpire
Sentiment: Positive
Shares of Exelixis, Inc. (EXEL), an oncology-focused biopharmaceutical firm, boosted by Big Money inflows.
Read More
Exelixis (EXEL) is a Great Momentum Stock: Should You Buy?
Published: May 19, 2025 by: Zacks Investment Research
Sentiment: Positive
Does Exelixis (EXEL) have what it takes to be a top stock pick for momentum investors? Let's find out.
Read More
Unlocking Exelixis (EXEL) International Revenues: Trends, Surprises, and Prospects
Published: May 19, 2025 by: Zacks Investment Research
Sentiment: Neutral
Explore Exelixis' (EXEL) international revenue trends and how these numbers impact Wall Street's forecasts and what's ahead for the stock.
Read More
Why Exelixis (EXEL) is a Top Growth Stock for the Long-Term
Published: May 15, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
Exelixis: A Notable Quarter
Published: May 14, 2025 by: Seeking Alpha
Sentiment: Positive
Exelixis just delivered a strong Q1 beat, raised 2025 guidance, and continues to benefit from robust Cabometyx sales and share buybacks. The company is transitioning to zanzalintinib as its next flagship drug, but pivotal trial success remains uncertain, and skepticism persists among analysts. The company has a rock-solid balance sheet with some $1.75 billion in cash and no long-term debt.
Read More
EXEL Q1 Earnings Beat, 2025 Sales View Up as Cabometyx Drives Top Line
Published: May 14, 2025 by: Zacks Investment Research
Sentiment: Positive
Exelixis' first-quarter earnings and sales beat estimates as lead drug Cabometyx maintains momentum. The company raises its sales guidance for 2025.
Read More
Will Exelixis (EXEL) Beat Estimates Again in Its Next Earnings Report?
Published: May 12, 2025 by: Zacks Investment Research
Sentiment: Positive
Exelixis (EXEL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Read More
About Exelixis, Inc. (EXEL)
- IPO Date 2000-04-17
- Website https://www.exelixis.com
- Industry Biotechnology
- CEO Michael M. Morrissey
- Employees 1147